Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2017-10-25 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
2017年第三季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled "2017年第三季度报告" which translates to "2017 Third Quarter Report." It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, cash flow information, and management commentary on financial performance and significant events during the quarter. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year clearly indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data rather than just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2017
2017-10-25 Chinese
关于第三届董事会第十六次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions from the 16th meeting of the third board of directors of the company. It specifically mentions the approval of the company's 2017 third quarter report and states that the report will be publicly released on October 26, 2017. The document itself does not contain the financial data or the full report but rather announces the board's approval and the upcoming release of the report. The document length is short (730 characters), and it fits the pattern of a meeting resolution announcement related to management decisions. Therefore, it is best classified as Board/Management Information (MANG).
2017-10-25 Chinese
2017年第三季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled '2017 年第三季度报告正文' which translates to '2017 Third Quarter Report'. It contains detailed financial data such as total assets, net profit, cash flow, earnings per share, and other financial indicators for the third quarter of 2017. It also includes management statements, shareholder information, and notes on financial performance and changes. The length of the document (8942 characters) and the presence of substantive financial data and analysis confirm it is a comprehensive quarterly financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q3 2017
2017-10-25 Chinese
关于第三届监事会第十四次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement of the resolution passed by the Supervisory Board regarding the review of the company's 2017 third quarter report. It states that the Supervisory Board has audited and approved the third quarter report, confirming its compliance and accuracy. The document itself does not contain the actual financial statements or detailed financial data of the third quarter report, but rather the approval and confirmation of that report by the Supervisory Board. The document length is short (666 characters), and it serves as a formal announcement of the Supervisory Board's resolution rather than the report itself. Therefore, it is not an Interim/Quarterly Report (IR) but rather a Regulatory Filing (RNS) as it is a compliance announcement related to the quarterly report.
2017-10-25 Chinese
关于公开发行可转换公司债券申请获中国证监会发行审核委员会审核通过的公告
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding the approval by the China Securities Regulatory Commission (CSRC) issuance review committee for the company's application to publicly issue convertible bonds. It mentions that the formal approval document is still pending and that a further announcement will be made upon receipt. The content focuses on a capital raising activity (issuance of convertible bonds) and is an update on financing status rather than a full financial report or detailed filing. The document length is short (499 characters), and it is clearly an announcement of a financing event. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2017-09-28 Chinese
关于《请做好相关项目发审委会议准备工作的函》相关问题的回复说明
Regulatory Filings Classification · 95% confidence The document is a detailed response from a company and its sponsor to a regulatory authority (China Securities Regulatory Commission) regarding specific questions raised in a formal letter about the company's convertible bond issuance and related stock pledge guarantees. It includes legal and regulatory references, detailed explanations, and confirmations from legal counsel and the sponsor institution. The document is not a financial report, earnings release, or management discussion, but rather a regulatory compliance response to a formal inquiry. It is not a brief announcement but a substantive reply to a regulatory letter. The document length is 5764 characters, which is substantial and contains detailed legal and regulatory analysis. This fits best under Regulatory Filings (RNS), as it is a regulatory compliance document responding to a regulatory request and does not fit other categories like Annual Report, Audit Report, or Capital Update. Therefore, the classification is RNS with high confidence.
2017-09-20 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.